New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCarnosine vs Mazdutide

Carnosine vs Mazdutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityRecovery & Repair
Carnosine
GLP-1 / Weight Loss Agonists
Mazdutide
Summary
Carnosine is an endogenous dipeptide (beta-alanine + histidine) found in high concentrations in muscle and brain. It is a potent anti-aging molecule with broad spectrum antioxidant, anti-glycation, anti-carbonylation, and metal chelating properties, making it one of the most protective naturally occurring dipeptides.
Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
Half-Life
~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis)
~7 days
Admin Route
Oral, Topical
SubQ
Research
Typical Dose
1,000–2,000 mg
1.5 mg → 3 mg → 4.5 mg → 6 mg
Frequency
Once to twice daily with meals
Once weekly
Key Benefits
  • Potent anti-glycation (prevents protein cross-linking/aging)
  • Broad-spectrum antioxidant in muscle and brain
  • Extends cell lifespan and protects telomeres
  • Improves muscle performance and delays fatigue (pH buffering)
  • Neuroprotective against Alzheimer's amyloid-beta
  • Wound healing acceleration
  • Anti-cataract properties (eye health)
  • Improves diabetes complications via AGE prevention
  • Chelates excess copper and zinc
  • Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
  • Significant reduction in liver fat content (NAFLD/MASH potential)
  • Improves HbA1c and fasting glucose in type 2 diabetes
  • Favorable lipid profile changes (reduced triglycerides)
  • Once-weekly subcutaneous dosing
  • Potential for superior weight loss vs GLP-1 monotherapy
Side Effects
  • Very well tolerated
  • Rare: mild GI discomfort at high doses
  • No significant adverse effects in human studies
  • Nausea
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +3 more
Stacks With